Atea Pharmaceuticals Stock Insiders

AVIR -  USA Stock  

USD 25.04  0.69  2.83%

Atea Pharmaceuticals employes about 39 people. The company is managed by 9 executives with total tenure of roughly 65 years, averaging almost 7.0 years of service per executive having 4.33 employees per reported executive. Discussion of Atea Pharmaceuticals management performance can provide insight into the enterprise performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Atea Pharmaceuticals future performance.
Please continue to Trending Equities.

Search Insiders 

 
Refresh
  Joseph Patti  CEO
President CEO, Director
  Russell Plumb  Chairman
Executive Chairman of the Board
  Mark Colonnese  President
CFO, Executive Vice President

Atea Pharmaceuticals Management Team Effectiveness

Atea Pharmaceuticals has return on total asset (ROA) of 1.7 % which means that it generated profit of $1.7 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (3.86) %, meaning that it created substantial loss on money invested by shareholders. Atea Pharmaceuticals management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of 08/01/2021, Return on Invested Capital is likely to grow to 0.07, while Return on Investment is likely to drop (20.28) . Atea Pharmaceuticals Total Assets are relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Total Assets of 863.63 Million. As of 08/01/2021, Current Assets is likely to grow to about 931.6 M, while Net Current Assets as percentage of Total Assets are likely to drop 102.91.
As of 08/01/2021, Issuance Purchase of Equity Shares is likely to grow to about 394.1 M, while Weighted Average Shares is likely to drop slightly above 19.4 M.

Atea Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of (22.51) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 24.7 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.25.

Atea Pharmaceuticals Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atea Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atea Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Atea Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Atea Pharmaceuticals Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Atea Pharmaceuticals Price Series Summation is a cross summation of Atea Pharmaceuticals price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Atea Pharmaceuticals Notable Stakeholders

An Atea Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Atea Pharmaceuticals often face trade-offs trying to please all of them. Atea Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Atea Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joseph Patti - President CEO, DirectorProfile
Russell Plumb - Executive Chairman of the BoardProfile
Mark Colonnese - CFO, Executive Vice PresidentProfile
John Richard - Independent DirectorProfile
Anne VanLent - Independent DirectorProfile
Michael Dunne - Independent DirectorProfile
Armando Anido - Independent DirectorProfile
Geoffrey Cox - Independent DirectorProfile
Michael Dougherty - Independent DirectorProfile

About Atea Pharmaceuticals Management Performance

The success or failure of an entity such as Atea Pharmaceuticals often depends on how effective the management is. Atea Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Atea Pharmaceuticals management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Atea Pharmaceuticals management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Investment(18.80) (20.28) 
Return on Average Assets(0.025) (0.0269) 
Return on Average Equity(0.044) (0.0452) 
Return on Invested Capital 0.07  0.07 
Return on Sales(0.20) (0.22) 
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.
The data published in Atea Pharmaceuticals' official financial statements usually reflect Atea Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Atea Pharmaceuticals. For example, before you start analyzing numbers published by Atea Pharmaceuticals accountants, it's critical to develop an understanding of what Atea Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Pharmaceutical Products space in which it operates.
Please note, the presentation of Atea Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atea Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Atea Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Atea Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Atea Pharmaceuticals' management to manipulate its earnings.

Atea Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Atea Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Atea Pharmaceuticals within its industry.

Atea Pharmaceuticals Manpower Efficiency

Return on Atea Pharmaceuticals Manpower

Revenue Per Employee1 M
Revenue Per Executive5.4 M
Net Loss Per Employee345.7 K
Net Loss Per Executive1.2 M
Working Capital Per Employee2.3 M
Working Capital Per Executive10.2 M
Today, most investors in Atea Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Atea Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Atea Pharmaceuticals per employee as a starting point in their analysis.

Per Employee

Atea Pharmaceuticals Per Employee Growth Over Time

Net Income Per Employee

(345,694)Share
Atea Pharmaceuticals Net Income Per Employee is relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Net Income Per Employee of (320,399)

Revenue Per Employee

1.02 MillionShare
Atea Pharmaceuticals Revenue Per Employee is relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Revenue Per Employee of 1.05 Million
Please continue to Trending Equities. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.